Bristol Myers Squibb (BMY) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Bristol Myers Squibb (BMY)

66.58

-0.37 (0.55%)

as of Aug 28, 2026, 8:00:00 pm Market Open.

162 watching

Investor Insights

Aug 30, 2026, 12:00 am

This summary was created by AI, based on 8 opinions in the last 12 months.

Bristol Myers Squibb (BMY) has garnered a mixed set of opinions from various analysts. Some reviewers highlight the company's strong performance in 2023, with a 19% increase in stock price and a robust free cash flow projected to hit $15 billion by 2027. The company is also noted for its attractive dividend yield exceeding 4% and a promising drug pipeline, which could support future growth. However, concerns have been raised regarding the disappointing sales of its Cobenfy drug, leading some experts to reassess their investment positions. Overall, there is a sense of cautious optimism about the potential for recovery if the growth portfolio can continue to outperform the legacy products.

Consensus

Mixed

Valuation

Undervalued

Similar

EliLilly,LLY

WEAK BUY

Their model price is just a couple of dollars over the current price. Prefers Amgen.

DON'T BUY

Has had a lot of problems. Starting to clear up, but will take awhile.

WEAK BUY

DON'T BUY

Has had problems in manufacturing, shipping and FDA approvals. Exoects slow earnings growth.

BUY

Likes the valuations. Good balance sheet and good earnings.

BUY

Looks cheap. There is an SEC investigation going on.

DON'T BUY

Now is a good time for drug stocks, but this company has corporate problems.

BUY

9.25% dividend. Has been hit hard. Stable cash flow.

TOP PICK

Has been oversold. Very cheap. Could be a takeover.

DON'T BUY

Could drop. Prefers generic drugs.

BUY

Good drug company, but had difficulties getting FDA approvals. Good dividend. Cheap.

BUY

Made some poor moves. Still a triple A company.

PAST TOP PICK

(Was a top pick on May 23. Down 31%). Fell with health care. Price looks very good.

BUY

Trading at 5 X Book. Good dividends. New drug has approval.

BUY

Likes the drug sector. Prefers Pfizer.

Showing 196 to 210 of 222 entries

Most Recent Experts

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Kevin Simpson

Capital Wealth Planning

Jim Lebenthal

Cerity Partners

Bill Baruch, Founder, Blue Line Capital

Blue Line Capital

Brianne Gardner

Raymond James

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Bristol Myers Squibb (BMY)